CRNX – crinetics pharmaceuticals, inc. (US:NASDAQ)

News

Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $87.00 price target on the stock.
Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer [Yahoo! Finance]
Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer
Crinetics Pharmaceuticals Announces December 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com